Announced
Completed
Synopsis
BioNTech, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, completed the acquisition of AexeRNA Therapeutics, a company developing mRNA therapeutics utilizing its proprietary next-generation programmable and highly potent Lipid Nanoparticle nucleic acid delivery system, for $1bn.
Principals
Show Details & Financials
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.